patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_282680 | REC_0007001 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12 | 59 | male | 0 | 11 | 5 | 2 | sotorasib 960 mg daily | 27.9 | true | MSI-H | 2026-03-15T05:35:58.570751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832631 | REC_0007002 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.6 | 47 | female | 0 | 14 | 3.9 | 6 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.570979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262496 | REC_0007003 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.5 | 65 | female | 0 | 32 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.2 | true | MSS | 2026-03-15T05:35:58.571210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652666 | REC_0007004 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.4 | 72 | female | 2 | 0 | 5.7 | 6 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:58.571438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238531 | REC_0007005 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 7.9 | 77 | female | 2 | 12 | 4.9 | 2 | alectinib 600 mg BID | 26.4 | false | MSS | 2026-03-15T05:35:58.571665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608552 | REC_0007006 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.3 | 63 | male | 1 | 2 | 5.1 | 5 | sotorasib 960 mg daily | 16 | true | MSS | 2026-03-15T05:35:58.571901+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237234 | REC_0007007 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 11.1 | 65 | female | 0 | 9 | 5.4 | 1 | osimertinib 80 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:58.572176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342963 | REC_0007008 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.6 | 66 | female | 0 | 23 | 4.6 | 6 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:58.572461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182096 | REC_0007009 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 4.3 | 74 | male | 1 | 13 | 3.8 | 6 | sotorasib 960 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:58.572700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845144 | REC_0007010 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.7 | 63 | female | 0 | 14 | 7.2 | 4 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:58.572934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520305 | REC_0007011 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 7 | 65 | male | 0 | 18 | 5 | 6 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:35:58.573170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355571 | REC_0007012 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 13.7 | 64 | male | 1 | 19 | 6.3 | 0 | alectinib 600 mg BID | 9.6 | false | MSI-H | 2026-03-15T05:35:58.573405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959474 | REC_0007013 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.1 | 82 | female | 2 | 6 | 3.5 | 1 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:35:58.573641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819759 | REC_0007014 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.9 | 66 | female | 1 | 22 | 6.6 | 5 | alectinib 600 mg BID | 9.6 | true | MSI-H | 2026-03-15T05:35:58.573875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500513 | REC_0007015 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 13.6 | 64 | female | 0 | 20 | 6.5 | 0 | entrectinib 600 mg daily | 28.2 | true | MSS | 2026-03-15T05:35:58.574109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406829 | REC_0007016 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 12.1 | 51 | female | 0 | 2 | 4.9 | 6 | alectinib 600 mg BID | 10.7 | true | MSI-H | 2026-03-15T05:35:58.574345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306710 | REC_0007017 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 6.7 | 59 | male | 1 | 22 | 4.2 | 7 | entrectinib 600 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:58.574576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852128 | REC_0007018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.4 | 58 | male | 0 | 17 | 5.7 | 8 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:35:58.574806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206451 | REC_0007019 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.1 | 75 | female | 2 | 31 | 5.5 | 2 | pembrolizumab 200 mg q3w | 28.1 | true | MSS | 2026-03-15T05:35:58.575040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443408 | REC_0007020 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.7 | 69 | female | 1 | 25 | 4.4 | 5 | entrectinib 600 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:58.575275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957370 | REC_0007021 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.5 | 66 | female | 0 | 32 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:58.575550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981008 | REC_0007022 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 9.8 | 71 | female | 1 | 10 | 6.8 | 6 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:58.575784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955121 | REC_0007023 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 10.2 | 64 | female | 1 | 30 | 3.2 | 6 | pembrolizumab 200 mg q3w | 7.3 | false | MSI-H | 2026-03-15T05:35:58.576023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737454 | REC_0007024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.9 | 68 | female | 0 | 20 | 4.8 | 6 | alectinib 600 mg BID | 16 | true | MSI-H | 2026-03-15T05:35:58.576352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242677 | REC_0007025 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 3.7 | 72 | female | 1 | 12 | 5.7 | 7 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:58.576583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163221 | REC_0007026 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.6 | 64 | male | 0 | 37 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.2 | true | MSS | 2026-03-15T05:35:58.576816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613479 | REC_0007027 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 9.9 | 71 | female | 2 | 44 | 5.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:35:58.577044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976792 | REC_0007028 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 35 | 10.7 | 66 | male | 0 | 23 | 3.4 | 2 | sotorasib 960 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:58.577281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_687895 | REC_0007029 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 17.9 | 81 | male | 2 | 8 | 5.3 | 1 | osimertinib 80 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:58.577518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557453 | REC_0007030 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.6 | 53 | male | 0 | 21 | 6.1 | 5 | entrectinib 600 mg daily | 5.7 | true | MSS | 2026-03-15T05:35:58.577752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620797 | REC_0007031 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 15.7 | 64 | male | 1 | 17 | 6.3 | 3 | pembrolizumab 200 mg q3w | 13.4 | false | MSI-H | 2026-03-15T05:35:58.577986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917950 | REC_0007032 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.6 | 60 | female | 1 | 11 | 3.7 | 5 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:58.578218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140729 | REC_0007033 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8 | 77 | female | 1 | 4 | 6.2 | 8 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:35:58.578447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766815 | REC_0007034 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 13.3 | 66 | female | 1 | 11 | 4.5 | 2 | sotorasib 960 mg daily | 17 | true | MSS | 2026-03-15T05:35:58.578727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462651 | REC_0007035 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.6 | 53 | female | 0 | 8 | 6.8 | 2 | alectinib 600 mg BID | 25.8 | true | MSS | 2026-03-15T05:35:58.578965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111439 | REC_0007036 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 6.6 | 55 | female | 1 | 20 | 5.9 | 8 | osimertinib 80 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:58.579198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237920 | REC_0007037 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 20 | 3.7 | 67 | female | 1 | 32 | 2.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:35:58.579427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758221 | REC_0007038 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 17.3 | 58 | male | 1 | 22 | 4.7 | 4 | osimertinib 80 mg daily | 8 | true | MSI-H | 2026-03-15T05:35:58.579661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721917 | REC_0007039 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 9.8 | 61 | female | 0 | 50 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:35:58.579891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664086 | REC_0007040 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 16 | 63 | male | 0 | 22 | 5.8 | 1 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:58.580176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812167 | REC_0007041 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.7 | 73 | female | 2 | 31 | 5.6 | 5 | entrectinib 600 mg daily | 8 | false | MSI-H | 2026-03-15T05:35:58.580416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149882 | REC_0007042 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 4.5 | 67 | male | 1 | 66 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.9 | true | MSS | 2026-03-15T05:35:58.580662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344722 | REC_0007043 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.8 | 61 | female | 1 | 18 | 4.9 | 1 | entrectinib 600 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:58.580900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272068 | REC_0007044 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.1 | 73 | female | 3 | 5 | 5 | 3 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:58.581131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981912 | REC_0007045 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 15 | 67 | male | 0 | 14 | 5.5 | 9 | osimertinib 80 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:58.581365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143354 | REC_0007046 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 13.3 | 59 | female | 1 | 13 | 4.1 | 2 | osimertinib 80 mg daily | 36.5 | true | MSS | 2026-03-15T05:35:58.581599+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734091 | REC_0007047 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 13.7 | 74 | male | 2 | 13 | 5.5 | 2 | sotorasib 960 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:35:58.581884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830848 | REC_0007048 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 17.2 | 69 | female | 0 | 23 | 7 | 6 | entrectinib 600 mg daily | 10 | false | MSI-H | 2026-03-15T05:35:58.582120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421536 | REC_0007049 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 2.9 | 67 | female | 1 | 33 | 3.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:35:58.582353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602141 | REC_0007050 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.2 | 65 | female | 0 | 47 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:58.582586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319665 | REC_0007051 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 14 | 70 | female | 1 | 20 | 4.8 | 4 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:58.582817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574337 | REC_0007052 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.1 | 69 | female | 1 | 8 | 5 | 5 | entrectinib 600 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.583050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516439 | REC_0007053 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 11.7 | 74 | female | 1 | 24 | 7.1 | 2 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:35:58.583280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915214 | REC_0007054 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7 | 75 | female | 1 | 64 | 4.1 | 6 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:35:58.583508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193802 | REC_0007055 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.5 | 81 | female | 2 | 10 | 5.7 | 2 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:58.583738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804455 | REC_0007056 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 36 | 14.9 | 60 | male | 0 | 11 | 7.4 | 6 | sotorasib 960 mg daily | 21 | true | MSS | 2026-03-15T05:35:58.583974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779601 | REC_0007057 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 8.6 | 68 | female | 1 | 18 | 4.5 | 2 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:35:58.584308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254154 | REC_0007058 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 20.4 | 58 | male | 1 | 12 | 5.6 | 5 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.584555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238130 | REC_0007059 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 5.4 | 81 | female | 1 | 10 | 4.7 | 6 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:58.584787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715364 | REC_0007060 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 16.2 | 56 | female | 0 | 10 | 5.5 | 7 | alectinib 600 mg BID | 14.9 | true | MSI-H | 2026-03-15T05:35:58.585078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900091 | REC_0007061 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 6.5 | 67 | female | 1 | 23 | 8.2 | 7 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.585310+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264035 | REC_0007062 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 5.4 | 75 | female | 2 | 13 | 6.1 | 1 | osimertinib 80 mg daily | 24.4 | true | MSS | 2026-03-15T05:35:58.585542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168813 | REC_0007063 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.8 | 72 | male | 1 | 40 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.9 | true | MSS | 2026-03-15T05:35:58.585776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985049 | REC_0007064 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.6 | 46 | female | 0 | 5 | 4 | 6 | osimertinib 80 mg daily | 8.1 | false | MSS | 2026-03-15T05:35:58.586011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450956 | REC_0007065 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 13.4 | 64 | female | 1 | 7 | 5.6 | 2 | entrectinib 600 mg daily | 19.9 | false | MSS | 2026-03-15T05:35:58.586245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166317 | REC_0007066 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 4.8 | 77 | female | 1 | 79 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.2 | true | MSS | 2026-03-15T05:35:58.586475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527655 | REC_0007067 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 32 | 7.6 | 68 | female | 0 | 18 | 6.8 | 2 | pembrolizumab 200 mg q3w | 21 | true | MSS | 2026-03-15T05:35:58.586703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834926 | REC_0007068 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 7.5 | 77 | male | 1 | 15 | 5.7 | 1 | entrectinib 600 mg daily | 21 | false | MSS | 2026-03-15T05:35:58.586935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406811 | REC_0007069 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12 | 63 | female | 0 | 7 | 4.6 | 7 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:58.587169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620610 | REC_0007070 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9 | 64 | female | 1 | 4 | 5.4 | 5 | alectinib 600 mg BID | 15.3 | false | MSS | 2026-03-15T05:35:58.587398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771044 | REC_0007071 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 6.2 | 73 | female | 1 | 16 | 3.9 | 6 | sotorasib 960 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:58.587634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502924 | REC_0007072 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6 | 55 | male | 1 | 70 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.4 | false | MSS | 2026-03-15T05:35:58.587865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757164 | REC_0007073 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 6.1 | 70 | female | 0 | 12 | 5.7 | 0 | alectinib 600 mg BID | 47.1 | false | MSS | 2026-03-15T05:35:58.588159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573482 | REC_0007074 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6 | 65 | male | 1 | 47 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.4 | false | MSS | 2026-03-15T05:35:58.588398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527481 | REC_0007075 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 6.7 | 69 | female | 1 | 4 | 3.9 | 7 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.588636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205341 | REC_0007076 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 9.2 | 73 | female | 2 | 55 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:58.588877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161822 | REC_0007077 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 13.2 | 65 | female | 0 | 23 | 4.4 | 1 | osimertinib 80 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:58.589114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901637 | REC_0007078 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.1 | 75 | female | 2 | 8 | 6.5 | 2 | sotorasib 960 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:58.589347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694361 | REC_0007079 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.7 | 78 | male | 1 | 35 | 4.3 | 8 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:35:58.589583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701103 | REC_0007080 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.7 | 57 | female | 1 | 33 | 3.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 27.6 | true | MSS | 2026-03-15T05:35:58.589817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413760 | REC_0007081 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 17.3 | 85 | female | 0 | 14 | 4.8 | 1 | osimertinib 80 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:35:58.590051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106758 | REC_0007082 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 6.7 | 62 | female | 0 | 15 | 4 | 7 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.590283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360716 | REC_0007083 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.6 | 68 | female | 0 | 56 | 4.3 | 4 | pembrolizumab 200 mg q3w | 12.1 | true | MSS | 2026-03-15T05:35:58.590509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405636 | REC_0007084 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.5 | 71 | female | 1 | 24 | 6.5 | 7 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:58.590738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909741 | REC_0007085 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 10.2 | 66 | male | 0 | 18 | 6.7 | 5 | entrectinib 600 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:58.590973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380316 | REC_0007086 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 14 | 7.4 | 72 | female | 4 | 14 | 6.2 | 2 | alectinib 600 mg BID | 26.3 | true | MSS | 2026-03-15T05:35:58.591258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902586 | REC_0007087 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.4 | 62 | female | 1 | 10 | 6 | 6 | osimertinib 80 mg daily | 8.5 | true | MSS | 2026-03-15T05:35:58.591499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398770 | REC_0007088 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 8.9 | 74 | male | 1 | 12 | 5 | 2 | sotorasib 960 mg daily | 17.8 | true | MSS | 2026-03-15T05:35:58.591731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844974 | REC_0007089 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 3.9 | 60 | female | 1 | 85 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 37.7 | false | MSS | 2026-03-15T05:35:58.591964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830214 | REC_0007090 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 8.3 | 75 | male | 1 | 48 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:35:58.592255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535930 | REC_0007091 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 15.2 | 65 | male | 0 | 16 | 5.6 | 4 | entrectinib 600 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:58.592510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114905 | REC_0007092 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.5 | 65 | male | 0 | 17 | 7.3 | 6 | alectinib 600 mg BID | 10.9 | true | MSI-H | 2026-03-15T05:35:58.592746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330711 | REC_0007093 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7 | 82 | female | 1 | 24 | 4.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:35:58.592974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457291 | REC_0007094 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 8.8 | 60 | female | 0 | 16 | 3.9 | 7 | osimertinib 80 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:58.593205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992052 | REC_0007095 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.6 | 73 | female | 2 | 39 | 2.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 21.3 | false | MSS | 2026-03-15T05:35:58.593437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350101 | REC_0007096 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.2 | 87 | female | 2 | 48 | 5.9 | 2 | pembrolizumab 200 mg q3w | 16 | true | MSS | 2026-03-15T05:35:58.593669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700736 | REC_0007097 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 7.9 | 54 | male | 0 | 17 | 5.1 | 7 | pembrolizumab 200 mg q3w | 18.1 | false | MSS | 2026-03-15T05:35:58.593900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677369 | REC_0007098 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 17.6 | 55 | female | 1 | 6 | 6.7 | 7 | entrectinib 600 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:35:58.594133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802390 | REC_0007099 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.2 | 63 | female | 1 | 15 | 4.5 | 4 | entrectinib 600 mg daily | 19 | false | MSS | 2026-03-15T05:35:58.594414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421595 | REC_0007100 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 5.9 | 66 | female | 0 | 83 | 6.8 | 5 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:35:58.594644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.